Moreover, circulating MCP-1 has been indicated as a prognosticator of increased CRC risk [32] and a component of cytokine panels differentiating CRC patients from those with high-risk conditions such as IBD and adenomas [33]. This evidence concerns the gene CCL2 and adenoma.